French pharmaceutical giant Sanofi has teamed up with Formation Bio and OpenAI to develop AI-powered software for drug development.

The collaboration aims to revolutionize the pharmaceutical industry by accelerating the introduction of new medications to patients.

Sanofi will provide exclusive data, Formation Bio will contribute engineering resources, and OpenAI will offer cutting-edge AI capabilities.

The goal is to create custom AI solutions to transform the drug development lifecycle and enhance productivity in delivering innovative treatments.

The partnership reflects Sanofi's commitment to becoming a biopharma leader powered by AI.

This collaboration follows previous partnerships with Owkin, Aqemia, and BioMap, which also focused on leveraging AI to improve patient outcomes and discover new treatments.